Issued Patents All Time
Showing 1–23 of 23 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12285431 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | Jay Copeland Strum, Patrick Joseph Roberts, Jessica A. Sorrentino | 2025-04-29 |
| 11717523 | Transient protection of normal cells during chemotherapy | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2023-08-08 |
| 11654148 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2023-05-23 |
| 11446295 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors | Jay Copeland Strum, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White | 2022-09-20 |
| 11395821 | Treatment of EGFR-driven cancer with fewer side effects | Jessica A. Sorrentino, Jay Copeland Strum, Andrew Beelen | 2022-07-26 |
| 11090306 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | Jay Copeland Strum, Patrick Joseph Roberts, Jessica A. Sorrentino | 2021-08-17 |
| 11040042 | Transient protection of normal cells during chemotherapy | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2021-06-22 |
| 10966984 | Transient protection of normal cells during chemotherapy | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2021-04-06 |
| 10925878 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2021-02-23 |
| 10709711 | Highly active anti-neoplastic and anti-proliferative agents | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2020-07-14 |
| 10660896 | Transient protection of normal cells during chemotherapy | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2020-05-26 |
| 10434104 | HSPC-sparing treatments for Rb-positive abnormal cellular proliferation | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2019-10-08 |
| 10413547 | Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitors | Jay Copeland Strum, Patrick Joseph Roberts, Jessica A. Sorrentino | 2019-09-17 |
| 10376519 | Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation | Jay Copeland Strum, Patrick Joseph Roberts, Ricky D. Gaston, Robert C. Gadwood | 2019-08-13 |
| 10231969 | Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors | Jay Copeland Strum, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White | 2019-03-19 |
| 10085992 | Transient protection of normal cells during chemotherapy | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2018-10-02 |
| 10076523 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2018-09-18 |
| 9931345 | Transient protection of normal cells during chemotherapy | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2018-04-03 |
| 9808461 | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 | Derek Dirocco, Norman E. Sharpless, Jay Copeland Strum, Patrick Joseph Roberts, Benjamin D. Humphreys +1 more | 2017-11-07 |
| 9717735 | Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation | Jay Copeland Strum, Patrick Joseph Roberts, Ricky D. Gaston, Robert C. Gadwood | 2017-08-01 |
| 9527857 | HSPC-sparing treatments for RB-positive abnormal cellular proliferation | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2016-12-27 |
| 9487530 | Transient protection of normal cells during chemotherapy | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2016-11-08 |
| 9464092 | Transient protection of normal cells during chemotherapy | Jay Copeland Strum, Patrick Joseph Roberts, Francis Xavier Tavares | 2016-10-11 |